201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://www.lyell.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 219
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Richard D. Klausner M.D. | Founder & Exec. Chairman | 510.17k | N/A | 1952 |
Dr. Lynn Seely M.D. | Pres, CEO & Director | 32.67k | N/A | 1959 |
Mr. Charles W. Newton | Chief Financial Officer | 1.75M | N/A | 1971 |
Mr. Stephen J. Hill | Chief Operating Officer | 808.12k | N/A | 1970 |
Ms. Elizabeth Homans | Consultant | 988.85k | N/A | 1966 |
Prof. Stanley R. Riddell M.D. | Founder & Scientific Advisor | N/A | N/A | N/A |
Dr. Crystal L. Mackall M.D. | Founder & Scientific Advisor | N/A | N/A | N/A |
Nellie Dillery | Director of Accounting | N/A | N/A | N/A |
Mr. Richard Goold Ph.D. | Chief Information Officer | N/A | N/A | 1960 |
Dr. Gary Lee Ph.D. | Chief Scientific Officer | N/A | N/A | 1977 |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc.’s ISS governance QualityScore as of 1 January 2023 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 8; Compensation: 10.